▎Edited by the content team of WuXi AppTecAccording to incomplete statistics from Innovation Radar, last week (February 17 to February 23), the global health sectorA total of 30 financing events were disclosed, with a total amount of nearly 5 billion yuan.。In terms of amount, there were 14 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 20 early-stage financings (before Series B) and 5 mid-to-late stage financings (Series B and later). A total of 8 companies in the biopharmaceutical field received financing, involving drug types including gene therapy, bispecific antibodies, peptides, etc.EG 427 Completes €27 Million Series B Financing
Keywords: Gene Therapy
Latest Financing:€27 Million Series B Financing
This round of investment institutions: Andera Partners, Bpifrance, SCI VenturesOn February 20, EG 427 announced the completion of a €27 million Series B financing round, which will be used to advance EG 427's early pipeline projects based on its HERMES vector technology platform and to study the safety and early efficacy of its first project targeting bladder dysfunction, EG110A.EG 427 is a biotechnology company dedicated to the development of precise gene therapies, focusing on the study of chronic disease pathologies in the field of neuro-urology.The company's first ongoing human study is expected to pave the way for the clinical development of treating neurogenic detrusor overactivity (NDO) in patients with spinal cord injuries. Its unique HERMES platform provides precise neuromodulatory therapeutics. With control over complex regulatory elements, its vector achieves focal transduction in specific areas, followed by selective transgene expression in targeted neuronal subpopulations. The nrHSV-1 vector has a proven clinical safety profile and potential for repeat dosing, with a large payload capacity enabling multifunctional DNA delivery for smarter gene medicine.
Cholesgen Completes Over 100 Million Yuan in Series A+ Financing
Keywords: Small Molecule Drugs
Latest Financing:Over 100 Million Yuan A+ Round
This round of investment institutions: AstraZeneca-CICC Healthcare Industry Fund, SDIC Venture CapitalNews on February 21: Recently, Cholesgen completed an A+ round of financing exceeding 100 million RMB. The funds from this financing will mainly be used to accelerate the advancement of multiple core pipelines into clinical applications and development, as well as the expansion of the research and development platform and team. Cholesgen is at the forefront of scientific research in the field of glycolipid metabolism, focusing on innovative drug targets with high druggability in the cholesterol metabolic pathway.Carry out innovative drug research and development work for major metabolic diseases (hyperlipidemia, obesity, diabetes, atherosclerosis, and MASH).. The original research project is transformed from Academician Song Baoliang's laboratory, committed to the concept of "Healthy Metabolism, Healthy Cardiovascular, Healthy Living," and strives to provide optional solutions for the treatment of patients with metabolic diseases.
Chimigen Bio CompletesOver 100 Million YuanPre-A Round Financing First Close
Keyword: Vaccine
Latest Financing:Over 100 Million YuanPre-A Round
This round of investment institutions: SDIC Venture, CAS StarNews on February 19: Recently, Chimigen Bio announced the completion of the first closing of its Pre-A round financing, with an amount exceeding 100 million yuan. This round of financing will be used to accelerate the global clinical trials of its core products SN3001 (a therapeutic vaccine for prostate cancer) and SN2001 (an immunotherapy vaccine for chronic hepatitis B), as well as the continuous development of tumor therapeutic vaccines based on the SynNeogen core technology platform. Chimigen Bio is a...Focus on the development of innovative immunotherapies in the two major disease areas of oncology and viral infections.A biotechnology company relying on the world's first SynNeogen immunotherapy platform technology, achieves a new type of immunotherapy for "cold tumor transformation" and functional cure through the development of DC cell functions.Zhi Tai Bio Receives $10 Million in Financing
Keywords: Polypeptides, Protein-based Drugs
Latest Financing:100 million yuan
This round of investment institutions: Aimeike, Guofengtou (Wuxi) Biotechnology Fund, BlueRun VenturesNews on February 17: Zhipin Biotech has recently secured another billion-yuan financing.Zhi Tai Bio focuses on developing innovative biopharmaceuticals for the treatment of chronic metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).The company's pipeline currently includes several innovative recombinant protein drugs and biosimilars under research, such as the biosimilar ZT001 of semaglutide injection, and ZT002, a novel ultra-long-acting GLP-1R agonist that has the potential to achieve once-a-month dosing.In addition, in November 2024, ZT Biotech's Class 1 new drug ZT006 tablets received the CDE clinical trial implied permission, intended for development to control blood sugar in adult patients with type 2 diabetes. Public information shows that ZT006 is a new generation of oral GLP-1 drug, belonging to a new generation of oral protein-based medicines.Reverb Therapeutics Completes $12 Million Seed Financing Round
Keywords: Bispecific Antibody
Latest Financing:$12 Million Seed Round
This round of investment institutions: Amplitude Ventures, Finchley Healthcare Ventures, InBC, KdT Ventures, Multiple Myeloma Research Foundation, etc.News on February 19: Reverb Therapeutics announced that it has completed a $12 million financing round led by Amplitude Ventures. The company's Amplify platform, throughEngineering of bispecific antibodies and data-driven modeling of antibody interactions to modulate the effects of endogenous cytokines and redirect them to potential therapeutic sitesThis approach effectively avoids systemic toxicity, immunogenicity, and manufacturing issues. Dr. David de Graaf, CEO of Reverb Therapeutics, stated that this financing will help advance its IL-15 bispecific research project into the candidate stage while developing other bispecific projects involving different cytokines and cell targets. Reverb Therapeutics' pipeline, AMP01, can block PD-1 while delivering endogenous IL-15, a key protein that amplifies and activates cytotoxic T cells.Moda Bio Completes Tens of Millions of Yuan in Series A1 Financing
Keywords: AI Drugs
Latest Financing:Tens of Millions of Yuan in Series A1 Round
This round of investment institutions: IMO Ventures, XtalPi, Yae CapitalOn February 14, META Pharmaceuticals Inc. announced the completion of a multi-million yuan A1 round of financing. This funding will be used forAccelerate the advancement of Meda Bio's two pipeline drugs in research towards clinical trials, and further expand the development of its AI-driven metabolic enzyme target discovery platform., achieving innovative target breakthroughs and pipeline asset transformation across more indications. Currently, the two most advanced pipeline drugs of Moda Bio are a small-molecule targeted innovative drug for autoimmune diseases and a small-molecule inhibitor for primary hyperoxaluria. Empowered by XtalPi's AI + robotics R&D platform, the small-molecule inhibitor for primary hyperoxaluria has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA. It is expected to complete the Investigational New Drug (IND) application and early clinical trials within the next one to two years. After this round of financing, Moda Bio will continue to advance its R&D collaboration with XtalPi, accelerating the entry of existing potential “first-in-class” pipeline drugs into clinical research. Furthermore, it will further invest in the development of its multi-omics analysis AI platform to build continuous self-sustaining capabilities and innovative barriers.Readers, please star⭐Chuangjianhui to receive push notifications第一时间收到推送.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress of global biopharmaceuticals and health. This article is for information exchange only, and the views in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation of treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media feeds, but unauthorized republication or reproduction in any form by media or institutions to other platforms is strictly prohibited. For authorization to republish, please contact:"Chuangjian Hui"Contact us through the WeChat Official Account message.
More Data Content RecommendedClick "InSee", Sharing New Health Trends from Creatheon"
